Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus

American Journal of Medicine

Volumn 120, Issue 3 SUPPL. 1, 2007, Pages

  Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular disease; Impaired glucose tolerance; Insulin resistance; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; FATTY ACID; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; GLYCATION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; UNITED STATES;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; EUROPE; GLUCOSE METABOLISM DISORDERS; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 33847187395     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.01.003     Document Type: Article

References (28)

1. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289 (2003) 76-79
2. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., and Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 286 (2001) 1195-1200
3. Reaven G.M. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
4. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., Lenfant C., and Conference Participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition [NHLBI/AHA Conference Proceedings]. Circulation 109 (2004) 433-438
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
6. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., and Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
7. McFarlane S.I., Banerji M., and Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86 (2001) 713-718
8. Peppa M., Uribarri J., and Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clinical Diabetes 21 (2003) 186-187
9. Tchernof A., Lamarche B., and Prud'homme D. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 19 (1996) 629-637
10. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81 (1998) 18B-25B
11. Meigs J.B., D'Agostino Sr. R.B., Wilson P.W.F., Cupples L.A., Nathan D.M., and Singer D.E. Risk variable clustering in the insulin resistance syndrome: the Framingham offspring study. Diabetes 46 (1997) 1594-1600
12. Schneider D.J., and Sobel B.E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A 88 (1991) 9959-9963
13. Chen Y.Q., Su M., Walia R.R., Hao Q., Covington J.W., and Vaughan D.E. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 273 (1998) 8225-8231
14. Brown N., Kim K.S., Chen Y.Q., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85 (2000) 336-349
15. Centers for Disease Control and Prevention, Publications and Products. National Diabetes Fact Sheet. General information and national estimates on diabetes in the United States (2005). http://www.cdc.gov/diabetes/pubs/factsheet05.htm Available at: http://www.cdc.gov/diabetes/pubs/factsheet05.htm.
16. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354 (1999) 617-621
17. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M., and Third National Health and Nutrition Examination Survey (NHANES III) and the National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
18. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., and Manson J.F. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25 (2002) 1129-1134
19. Hanley A.J.G., Williams K., Stern M.P., and Haffner S.M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25 (2002) 1177-1184
20. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
21. Alberti K.G., Zimmet P.Z., and WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
22. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
23. Bierman E.L. George Lyman Duff Memorial Lecture: atherogenesis in diabetes. Arterioscler Thromb 12 (1992) 647-656
24. Petersen K.F., and Shulman G.I. Etiology of insulin resistance. Am J Med 119 suppl 1 (2006) S10-S16
25. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 28 suppl 1 (2005) S4-S36
26. Tuomilehto J., Lindstrom J., Eriksson J.G., et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
27. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
28. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20 (1997) 537-544